Related Experiment Video
Updated: Apr 10, 2026
08:21
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
5.8K
Renin Genetic Polymorphism in Heart Failure Patients
Summary
This study found that A/G renin genetic polymorphism does not appear to play a role in the development of heart failure (HF). Researchers analyzed renin gene variations in HF patients and control groups, observing no significant association with HF pathogenesis.
Area of Science:
- Cardiovascular Genetics
- Molecular Cardiology
- Hypertension Research
Background:
- The renin-angiotensin-aldosterone system (RAAS) is crucial in regulating blood pressure and fluid balance.
- Genetic variations within the RAAS, including renin, are implicated in the pathogenesis of cardiovascular diseases such as hypertension (HTN), ischemic heart disease (IHD), and heart failure (HF).
Purpose of the Study:
- To investigate the association between A/G renin genetic polymorphism and the occurrence of heart failure (HF).
- To analyze the prevalence of specific renin gene polymorphisms in patients with established HF compared to a control group.
Main Methods:
- A cohort of 83 subjects was studied, including 43 patients diagnosed with heart failure (NYHA class III-IV) and 40 healthy individuals as a control group.
- Renin polymorphism was analyzed using the polymerase chain reaction (PCR) amplification method.
- Biomarkers such as NT-proBNP and cardiovascular risk factors (lipids, obesity, diabetes) were assessed in all participants.
Main Results:
- Ischemic heart disease (IHD) was the primary etiology of heart failure in 60.46% of the patient cohort.
- The A/G renin genetic polymorphism, considered to have pathogenic potential, was present in 60.46% of heart failure patients (4.65% homozygote, 55.81% heterozygote).
- In contrast, the heterozygote form of this polymorphism was found in only 37.5% of control subjects. Pathogenic mutations were also noted in hypertensive patients (38.46%), and those with obesity/overweight (55.88%) and diabetes (22.22%).
Conclusions:
- The study concluded that A/G renin polymorphisms do not appear to be significantly involved in the pathogenesis of heart failure (HF).
- While the A/G renin polymorphism was more prevalent in HF patients than controls, this association did not meet statistical significance for a causal role in HF development.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
01:29Heart Failure II: Pathophysiology
1.5K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.5K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
01:22Heart Failure Drugs: Diuretics
1.2K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.2K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
122
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
122
01:30Heart Failure V: Medical Management
567
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
567